753015-96-2

Basic information

• Product Name: TERT-BUTYL3-VINYLPYRROLIDINE-1-CARBOXYLATE
• Synonyms: 1-Pyrrolidinecarboxylicacid, 3-ethenyl-, 1,1-dimethylethyl ester;1-Boc-3-vinylpyrrolidine;TERT-BUTYL3-VINYLPYRROLIDINE-1-CARBOXYLATE
• CAS NO: 753015-96-2
• Molecular Formula: C₁₁H₁₉NO₂
• Molecular Weight: 197.27
• Mol File: 753015-96-2.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 248.4±29.0 °C(Predicted)
• Appearance: /
• Density: 1.050±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: -1.75±0.40(Predicted)
• CAS DataBase Reference: TERT-BUTYL3-VINYLPYRROLIDINE-1-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL3-VINYLPYRROLIDINE-1-CARBOXYLATE(753015-96-2)
• EPA Substance Registry System: TERT-BUTYL3-VINYLPYRROLIDINE-1-CARBOXYLATE(753015-96-2)

Safety Data

• Hazardous Substances Data: 753015-96-2(Hazardous Substances Data)

Usage

General Description

TERT-BUTYL3-VINYLPYRROLIDINE-1-CARBOXYLATE is a chemical compound commonly used in the pharmaceutical and agrochemical industries. It is a derivative of pyrrolidine-1-carboxylic acid and features a tert-butyl and vinyl substituent. TERT-BUTYL3-VINYLPYRROLIDINE-1-CARBOXYLATE is known for its ability to act as a versatile building block in the synthesis of various pharmaceuticals and agrochemicals. It is also used as a stabilizer in some formulations. Additionally, TERT-BUTYL3-VINYLPYRROLIDINE-1-CARBOXYLATE is a potential precursor for the preparation of biologically active compounds and is under ongoing research for its potential use in the development of new drugs and agrochemical products.

Upstream product

• 59379-02-1 tert-butyl 3-formylpyrrolidine-1-carboxylate 
• 1779-49-3 Methyltriphenylphosphonium bromide 

Relevant articles and documents

THERAPEUTIC METHODS

The invention provides methods and compositions for delivering a nucleic acid to a cell or the cytosol of the target cell. The method includes contacting the cell with, 1) a membrane-destabilizing polymer; and 2) a nucleic acid conjugate. The nucleic acid conjugate includes a targeting ligand bound to an optional linker and a nucleic acid.

Polysubstituted-indazole compounds and application of same as IDO inhibitors

The invention discloses polysubstituted-indazole compounds as shown in a formula (I) which is described in the specification, a preparation method for the compounds, and application of the compounds as IDO inhibitors. The compounds provided by the invention can be used for preventing and/or treating a plurality of diseases, such as Alzheimer's disease, cataract, infections related to cellular immune activation, autoimmune diseases, AIDS, cancers, depression, the metabolic disorder of tryptophan or the like.

Arylvinylazacycloalkane compounds and methods of preparation and use thereof

Novel vinylazacycloalkane compounds of Formula (I) are disclosed. The compounds are ligands of various nAChRs. The compounds and their pharmaceutically acceptable salts can be used to prepare pharmaceutical compositions and/or medicaments intended to prevent or treat disorders associated with dysfunction of nAChRs, especially within the central nervous system or the gastrointestinal system. Examples of types of disorders that can be treated include neurodegenerative disorders, including central nervous system disorders such as Alzheimer's disease, cognitive disorders, motor disorders such as Parkinson's disease, drug addiction, behavioral disorders and inflammatory disorders within the gastrointestinal system. The compounds can also serve as analgesics in the treatment of acute, chronic or recurrent pain.